JacobSchachterMD

Cardiology • Brooklyn, NY

Echocardiography, Non-Invasive Cardiology

Physician

Join to view full profile

Dr. Schachter is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Schachter's full profile

Already have an account?

Office
937 56th St
Brooklyn, NY 11219
Phone+1 718-972-2277

Education & Training

Maimonides Medical CenterFellowship, Cardiovascular Disease, 1985 - 1987
One Brooklyn Health System/Brookdale University Hospital and Medical CenterResidency, Internal Medicine, 1982 - 1985
State University of New York Downstate Medical Center College of MedicineClass of 1982

Certifications & Licensure

NY State Medical License 1984 - 2025
American Board of Internal Medicine Internal Medicine

Clinical Trials

Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients Start of enrollment: 2006 Jan 01
Unknown status
Phase 2
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma Start of enrollment: 2005 Jul 01
Unknown status
Phase 2
Safety Study of 188Re-PTI-6D2 in Patients With Metastatic Melanoma Start of enrollment: 2007 May 01
Completed
Phase 1
Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Ovarian Start of enrollment: 2018 Jan 21
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

186 citations
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
Richard D. Carvajal, Sophie Piperno-Neumann, Ellen Kapiteijn, Paul B. Chapman, Stephen Frank
Journal of Clinical Oncology. 2018-03-12
860 citations
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
Jacob Schachter, Antoni Ribas, Georgina V. Long, Ana Arance, Jean-Jacques Grob
Lancet. 2017-10-21
57 citations
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma.
Caroline Robert, Wen-Jen Hwu, Omid Hamid, Antoni Ribas, Jeffrey S. Weber
European Journal of Cancer. 2021-02-01

Press Mentions

There’s Good News About CancerMarch 7th, 2016

Other Languages

Hebrew